Your browser doesn't support javascript.
loading
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients.
Carnero Contentti, Edgar; López, Pablo A; Rojas, Juan I.
Afiliação
  • Carnero Contentti E; Neuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
  • López PA; Neuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
  • Rojas JI; Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina.
Expert Opin Emerg Drugs ; 27(1): 91-98, 2022 03.
Article em En | MEDLINE | ID: mdl-35341428
INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD) are rare but often devastating neuroinflammatory autoimmune diseases of the central nervous system. Acute treatment is critically important and it should be initiated early and aggressively, as relapses result in severe residual disability. Acute treatments are still based on clinical experience and observational studies. The most commonly used treatments are steroids and plasmapheresis. Several new treatments to improve management and recovery after relapses in NMOSD are currently under investigation. AREAS COVERED: This review discusses current and the most recent advances in active development of phase II/III clinical trials for acute treatment options and therapeutic strategies that can help management improvement of NMOSD during a relapse. These treatments include bevacizumab, ublituximab and HBM9161. EXPERT OPINION: NMOSD relapses require prompt evaluation and timely treatment to restore function and mitigate disability. Timing is critical. Plasmapheresis showed better outcomes in terms of recovery when compared to high-dose intravenous methylprednisolone alone. Some groups suggest that plasmapheresis could be considered as an initial treatment approach in different clinical scenarios due to its higher effectiveness. Future research and/or real-world data will establish the advantages and disadvantages of these new treatments and define the appropriate patient profile.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuromielite Óptica Tipo de estudo: Observational_studies Limite: Adult / Humans Idioma: En Revista: Expert Opin Emerg Drugs Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Argentina País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuromielite Óptica Tipo de estudo: Observational_studies Limite: Adult / Humans Idioma: En Revista: Expert Opin Emerg Drugs Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Argentina País de publicação: Reino Unido